Madrigal Mental Care Overview
Madrigal Mental Care is focused on using nanotechnology to accurately deliver psychedelic drugs for the treatment of mental health conditions such as post-traumatic stress disorder (PTSD). The company's Nanovo intranasal spray is designed to deliver active, nanoencapsulated psychedelic substances directly to the brain for rapid, safe, and efficient uptake. Madrigal utilizes molecules composed of psychedelic drugs such as psilocybin, ketamine, mescaline, MDMA, and more. By fundamentally changing the coding in the brain, rather than simply treating symptoms, the company is able to offer a transformative solution with minimal side effects.
Latest News
growth-positive
Madrigal Announces Groundbreaking Ketamine Research for PTSD Treatment and Upcoming In-Human Clinical Trials
Madrigal Mental Care has announced the successful completion of its nanotechnology research on the use of Ketamine for treating trauma-related disorders like PTSD and depression. The company is now preparing to initiate in-human clinical trials. The research highlights the potential of Ketamine combined with Madrigals proprietary nanotechnology to offer a transformative approach to PTSD treatment. The company aims to begin human trials this year and expedite FDA approval processes, aiming to provide a revolutionary treatment by 2026.
InvestmentExpand
growth-positive
Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs
Madrigal Mental Care, a biopharmaceutical company, introduces its novel nanotechnology for the treatment and prevention of post-traumatic stress disorder (PTSD) at Biomed Israel 2022. The company has developed a breakthrough nasal spray that enables nose-to-brain delivery of biodegradable nanoparticles encapsulating psychedelic substances. The technology was developed by Prof. Amnon Sintov of Ben-Gurion University of the Negev and licensed from BGN Technology. The nanotechnology platform allows for the precise and safe delivery of psychoactive substances, offering a new approach to psychedelic-based treatments. Madrigal Mental Care aims to begin preclinical trials with rodents and achieve efficacy and safety approvals to start first-in-human clinical trials next year. The companys technology has the potential to revolutionize the field of mental health care.
PartnersInvestment
growth-positive
Novel nasal spray delivers psychedelic drugs for PTSD
Israeli biopharmaceutical company Madrigal Mental Care is developing a novel nasal spray to deliver psychedelic drugs to the brain for treating and preventing post-traumatic stress disorder (PTSD). The company will introduce the nanotechnology-based delivery system at the Biomed Israel 2022 conference. The experimental spray contains biodegradable nanoparticles encapsulating molecules of psychedelic substances. The technology was licensed to Madrigal Mental Care by BGN Technologies. The company aims to begin first-in-human clinical trials next year.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | www.madrigal-psy.com/ |
Locations
Re'im, Israel
Photos & Videos
No files yet
Madrigal Mental Care Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsMedical Devices IndustryMedical ProductsCore Technology
Materials & SubstancesNanomaterialsBiologicalsMoleculesTags (9)
drug-developmenttreatmentsbiopharmaceuticalnanotechnologybiotechnologydrug-deliverypharmaceuticalsbiodegradablemental-healthMadrigal Mental Care Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
0
Total rounds
0
Investors
Madrigal Mental Care Lifecycle
Madrigal Mental Care News
3 articles
growth-positive
Madrigal Announces Groundbreaking Ketamine Research for PTSD Treatment and Upcoming In-Human Clinical Trials
Madrigal Mental Care has announced the successful completion of its nanotechnology research on the use of Ketamine for treating trauma-related disorders like PTSD and depression. The company is now preparing to initiate in-human clinical trials. The research highlights the potential of Ketamine combined with Madrigals proprietary nanotechnology to offer a transformative approach to PTSD treatment. The company aims to begin human trials this year and expedite FDA approval processes, aiming to provide a revolutionary treatment by 2026.
InvestmentExpand
growth-positive
Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs
Madrigal Mental Care, a biopharmaceutical company, introduces its novel nanotechnology for the treatment and prevention of post-traumatic stress disorder (PTSD) at Biomed Israel 2022. The company has developed a breakthrough nasal spray that enables nose-to-brain delivery of biodegradable nanoparticles encapsulating psychedelic substances. The technology was developed by Prof. Amnon Sintov of Ben-Gurion University of the Negev and licensed from BGN Technology. The nanotechnology platform allows for the precise and safe delivery of psychoactive substances, offering a new approach to psychedelic-based treatments. Madrigal Mental Care aims to begin preclinical trials with rodents and achieve efficacy and safety approvals to start first-in-human clinical trials next year. The companys technology has the potential to revolutionize the field of mental health care.
PartnersInvestment
growth-positive
Novel nasal spray delivers psychedelic drugs for PTSD
Israeli biopharmaceutical company Madrigal Mental Care is developing a novel nasal spray to deliver psychedelic drugs to the brain for treating and preventing post-traumatic stress disorder (PTSD). The company will introduce the nanotechnology-based delivery system at the Biomed Israel 2022 conference. The experimental spray contains biodegradable nanoparticles encapsulating molecules of psychedelic substances. The technology was licensed to Madrigal Mental Care by BGN Technologies. The company aims to begin first-in-human clinical trials next year.
CustomersPartners
Madrigal Mental Care Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Madrigal Mental Care Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 88/100 |
| Missing | video or image, funding rounds, markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 516466091 |
| Phone | +972 547727111 |
| Creator | Maor Perlov |
| Creator email | maorperlov@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-07-23T00:00:00.000Z |
| Created | 2022-05-10T00:00:00.000Z |
| Claimed | Yes |